查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1291420

抗高脂血症藥物市場：2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測

Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

市場概況：

2022年，全球抗高脂血症藥物市場規模達到120億美元。展望未來，IMARC Group預計，到2028年，市場規模將達到160億美元，在2023-2028年期間呈現4.6%的成長率（CAGR）。

抗高血脂藥物有助於降低血液中的膽固醇和各種脂質的血清水平。它們可以與不同的藥物一起服用，以控制高膽固醇和減少某些醫療狀況的風險。目前，它們的不同類別在全世界範圍內都有，可以根據病人的膽固醇情況、潛在疾病和其他因素給予治療。一些常用的抗高脂血症藥物包括他汀類、抗高脂血症組合、膽汁酸螯合劑、膽固醇吸收抑製劑、纖維酸衍生物和PCSK9抑製劑。

抗高脂血症藥物的市場趨勢：

由於久坐的生活方式、尼古丁成癮和大量食用高脂肪食物，高脂血症的發病率越來越高，這是催化抗高脂血症藥物需求的關鍵因素之一。此外，高脂血症增加了患冠狀動脈疾病（CAD）的風險，這是全世界成年人最常見的死亡原因。因此，對這些藥物的需求上升，以減少高水平的低密度脂蛋白（LDL）膽固醇和甘油三酯，同時增加高密度脂蛋白（HDL）膽固醇的低水平。除此以外，它們還被用於治療兒童的高膽固醇水平和各种血脂紊亂。此外，兒科人群中遺傳性和獲得性脂質和脂蛋白代謝紊亂的數量激增，對抗高脂血症藥物的需求產生了積極影響，以減少住院率和過早死亡。此外，新的和先進的藥物的批准正在為市場創造一個有利的前景。除此之外，世界各地的藥物化學家正在設計、合成和評估這些藥物的各種新分子，預計這將促進市場的成長。

本報告中回答的關鍵問題：

  • 2022年全球抗高脂血症藥物市場的規模是多少？
  • 2023-2028年全球抗高脂血症藥物市場的預期成長率是多少？
  • 推動全球抗高脂血症藥物市場的關鍵因素是什麼？
  • COVID-19對全球抗高脂血症藥物市場的影響是什麼？
  • 全球抗高脂血症藥物市場基於藥物類別的詳細情形是什麼？
  • 基於配銷通路的全球抗高脂血症藥物市場的詳細情形如何？
  • 全球抗高脂血症藥物市場的主要地區有哪些？
  • 誰是全球抗高脂血症藥物市場的主要參與者/公司？

目錄

第一章：前言

第二章：範圍和方法

  • 研究的目標
  • 利益相關者
  • 數據來源
    • 主要來源
    • 二級來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第三章：執行摘要

第四章：簡介

  • 概述
  • 主要行業趨勢

第五章：全球抗高脂血症藥物市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第六章：按藥物類別分類的市場

  • 他汀類藥物
    • 市場趨勢
    • 市場預測
  • 膽汁酸螯合劑
    • 市場趨勢
    • 市場預測
  • 膽固醇吸收抑製劑
    • 市場趨勢
    • 市場預測
  • 纖維酸衍生物
    • 市場趨勢
    • 市場預測
  • PCSK9抑製劑
    • 市場趨勢
    • 市場預測
  • 組合藥物
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第7章：按給藥途徑分類的市場

  • 口服
    • 市場趨勢
    • 市場預測
  • 靜脈注射
    • 市場趨勢
    • 市場預測

第8章：按配銷通路分類的市場

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 零售店
    • 市場趨勢
    • 市場預測
  • 網上零售商
    • 市場趨勢
    • 市場預測

第九章：按地區分類的市場

  • 北美洲
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場預測
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場預測
    • 日本
      • 市場趨勢
      • 市場預測
    • 印度
      • 市場趨勢
      • 市場預測
    • 韓國
      • 市場趨勢
      • 市場預測
    • 澳大利亞
      • 市場趨勢
      • 市場預測
    • 印尼
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場預測
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 義大利
      • 市場趨勢
      • 市場預測
    • 西班牙
      • 市場趨勢
      • 市場預測
    • 俄羅斯
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場預測
    • 墨西哥
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家分類的市場
    • 市場預測

第十章：SWOT分析

  • 概述
  • 優勢
  • 劣勢
  • 機會
  • 威脅

第十一章：價值鏈分析

第十二章：波特五力分析

  • 概述
  • 買方的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第十三章：價格分析

第十四章：競爭格局

  • 市場結構
  • 主要參與者
  • 主要參與者的概況
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112023A5622

Market Overview:

The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report:

  • What was the size of the global antihyperlipidemic drugs market in 2022?
  • What is the expected growth rate of the global antihyperlipidemic drugs market during 2023-2028?
  • What are the key factors driving the global antihyperlipidemic drugs market?
  • What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
  • What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
  • What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
  • What are the key regions in the global antihyperlipidemic drugs market?
  • Who are the key players/companies in the global antihyperlipidemic drugs market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Antihyperlipidemic Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Class

  • 6.1  Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4  Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5  PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6  Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7  Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7   Market Breakup by Route of Administration

  • 7.1  Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8   Market Breakup by Distribution Channel

  • 8.1  Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10  SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2  AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3  Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4  Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5  Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6  Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7  Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2022
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players